40 ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2006 ASTRAZENECA DEVELOPMENT PIPELINE 1 FEBRUARY 2007 Estimated filing date Therapy area Compound Mechanism Areas under investigation Europe US PRE-CLINICAL: NCEs AZD6370 diabetes 2009 2009 AZD8593 haemostasis 2009 2009 AZD4121 cholesterol absorption inhibitor dyslipidaemia 2009 2009 Cardiovascular AZD1283 thrombosis 2009 2009 AZD5861 dyslipidaemia 2009 2009 AZD1656 diabetes obesity 2009 2009 AZD3988 diabetes obesity 2009 2009 AZD2066 GERD 2009 2009 Gastrointestinal AZD5329 functional GI disease 2009 2009 AZD3102 Alzheimers disease 2009 2009 AZD6538 neuropathic pain 2009 2009 AZD8797 multiple sclerosis 2009 2009 AZD1940 nociceptive and neuropathic pain 2009 2009 AZD3241 Parkinsons disease 2009 2009 AZD2066 analgesia 2009 2009 Neuroscience AZD6280 anxiety 2009 2009 AZD1386 analgesia 2009 2009 AZD2624 schizophrenia 2009 2009 AZD0328 Alzheimers disease 2009 2009 AZD3043 GABA-A receptor modulator short-acting anaesthetic 2009 2009 AZD7903 analgesia 2009 2009 AZD9935 VEGF signalling inhibitor VEGFR-TKI solid tumours 2009 2009 AZD0424 SRC kinase inhibitor solid tumours 2009 2009 AZD5180 anti-angiogenic solid tumours 2009 2009 AZD1845 solid tumours 2009 2009 AZD8330 solid tumours 2009 2009 AZD3646 solid tumours and haematological malignancies 2009 2009 Oncology AZD9468 solid tumours 2009 2009 AZD2932 solid tumours 2009 2009 AZD4992 2009 2009 CAT-8015 recombinant immunotoxin haematological malignancies 2009 2009 CAT-5001 recombinant immunotoxin solid tumours 2009 2009 AZD6918 solid tumours 2009 2009 AZD6067 protease inhibitor COPD 2009 2009 AZD6357 osteoarthritis 2009 2009 AZD7928 COPD 2009 2009 AZD2392 asthma 2009 2009 AZD3825 asthma 2009 2009 AZD1236 COPD 2009 2009 AZD5069 COPD 2009 2009 Respiratory and AZD9668 COPD 2009 2009 Inflammation AZD9215 asthma 2009 2009 AZD1678 asthma 2009 2009 AZD8848 asthma 2009 2009 AZD8075 asthma 2009 2009 AZD6605 osteoarthritis 2009 2009 CAM-3001 rheumatoid arthritis 2009 2009 AZD3199 asthma COPD 2009 2009 Infection AZD5099 infection 2009 2009 Abbreviations used in the above table are explained in the Glossary on pages 179 and 180.
DIRECTORS REPORT 41 Business Review Estimated filing date Therapy area Compound Mechanism Areas under investigation Europe US PHASE I: NCEs AZD2479  enhancer dyslipidaemia 2009 2009 AZD1175 diabetes obesity 2009 2009 Cardiovascular AZD2207 diabetes obesity 2009 2009 AZD1305 antiarrhythmic arrhythmias 2009 2009 AZD9272 glutamate receptor modulator neuropathic pain 2009 2009 AZD2327 enkephalinergic receptor modulator anxiety and depression 2009 2009 Neuroscience AZD5904 enzyme inhibitor multiple sclerosis 2009 2009 AZD1080 Alzheimers disease 2009 2009 AZD3783 anxiety and depression 2009 2009 AZD0530 SRC kinase inhibitor solid tumours and haematological malignancies 2009 2009 AZD1152 aurora kinase inhibitor solid tumours and haematological malignancies 2009 2009 AZD4769 solid tumours 2009 2009 AZD2281 PARP inhibitor breast cancer 2009 2009 Oncology AZD4877 solid tumours 2009 2009 AZD1689 hypoxia activated cytotoxic solid tumours 2009 2009 AZD8931 solid tumours 2009 2009 AZD7762 solid tumours 2009 2009 AZD5672 rheumatoid arthritis 2009 2009 AZD6703 rheumatoid arthritis 2009 2009 AZD4818 COPD 2009 2009 Respiratory and Inflammation CAT-354 anti-IL-13 antibody asthma 2009 2009 AZD5904 COPD 2009 2009 AZD1744 asthma 2009 2009 PHASE II: NCEs Crestor ABT-335 Abbott statin fibrate fixed combination dyslipidaemia 2009 AZD9684 CPU inhibitor thrombosis 2009 2009 AZD0837 thrombin inhibitor thrombosis 2009 2009 Cardiovascular AZD6610 PPAR alpha with partial gamma dyslipidaemia 2009 2009 dapagliflozin BMS sodium-glucose cotransporter-2 SGLT2 inhibitor diabetes 2009 2009 AZD9056 ion channel blocker P2X7 inflammatory bowel disease 2009 2009 Gastrointestinal AZD3355 inhibitor of transient lower oesophageal GERD 2009 2009 sphincter relaxations TLESR PN-400 Pozen naproxen esomeprazole signs and symptoms of OA and RA 2009 2009 Neuroscience AZD3480 neuronal nicotinic receptor agonist cognitive disorders in schizophrenia 2009 2009 AZD3480 neuronal nicotinic receptor agonist Alzheimers disease 2009 2009 Zactima VEGF EGF TKI inhibitor with RET kinase activity medullary thyroid cancer 2H 2008 2H 2008 ZD4054 endothelin A receptor antagonist prostate cancer 2009 2009 Oncology AZD5896 AGT inhibitor solid tumours 2009 2009 AZD6244 ARRY-142886 MEK inhibitor solid tumours 2009 2009 CAT-3888 recombinant immunotoxin hairy cell hairy cell leukaemia 2009 2009 AZD9056 ion channel blocker P2X7 rheumatoid arthritis 2009 2009 Respiratory and Inflammation AZD1981 asthma 2009 2009 Infection CytoFab anti-TNF-alpha polyclonal antibody severe sepsis 2009 2009 PHASE II: LINE EXTENSIONS 1 Gastrointestinal Nexium proton pump inhibitor extra-oesophageal reflux disease 2009 2009 Oncology Iressa EGFR-TK inhibitor breast cancer 2009 2009 1 Project Extraesophageal reflux disease reflux asthma will be completed but will not result in a regulatory filing.
42 ASTRAZENECA ANNUAL REPORT AND FORM 20-F INFORMATION 2006 ASTRAZENECA DEVELOPMENT PIPELINE 1 FEBRUARY 2007 CONTINUED Estimated filing date Therapy area Compound Mechanism Areas under investigation Europe US PHASE III: NCEs AGI-1067 anti-atherogenic atherosclerosis 4Q20072Q 3Q2007  ADP receptor antagonist arterial thrombosis 2009 2009 saxagliptin BMS dipeptidyl peptidase-4 DPP-4 inhibitor diabetes 2009 1H 2008 Zactima VEGF EGF TKI inhibitor with RET kinase activity NSCLC 2H 2008 2H 2008 Oncology 2 Recentin AZD2171 VEGF signalling inhibitor VEGFR-TKI NSCLC and CRC 2009 2009 PHASE III: LINE EXTENSIONS Atacand angiotensin II antagonist diabetic retinopathy 2009 2009 Atacand Plus angiotensin II antagonist thiazide diuretic 32 12.5 mg, 32 25 mg for hypertension 2H 2008 Crestor statin atherosclerosis Filed Filed Cardiovascular Crestor statin outcomes CHF 2H 2008 2H 2008 Crestor statin outcomes End Stage Renal Disease 2009 2009 Seloken Toprol-XL beta-blocker HCTZ combination Approved 3 Nexium proton pump inhibitor NSAID GI side effects symptom resolution Promotable Filed Nexium proton pump inhibitor NSAID GI side effects ulcer healing Launched Filed Nexium proton pump inhibitor peptic ulcer bleeding 1H 2008 1H 2008 Gastrointestinal Nexium sachet formulation proton pump inhibitor GERD Filed Approved Nexium low dose proton pump inhibitor low dose aspirin associated peptic ulcer 2009 2009 aspirin combination Seroquel SR D 5HT antagonist schizophrenia Filed Filed 2 2 Seroquel D 5HT antagonist bipolar maintenance 4Q 2007 2Q 2007 2 2 Seroquel D 5HT antagonist bipolar depression 4Q 2007 Approved 2 2 Neuroscience Seroquel SR D 5HT antagonist generalised anxiety disorder 2H 2008 1H 2008 2 2 Seroquel SR D 5HT antagonist major depressive disorder 2H 2008 1H 2008 2 2 Seroquel SR D 5HT antagonist bipolar mania 1H 2008 1H 2008 2 2 Seroquel SR D 5HT antagonist bipolar depression 1H 2008 1H 2008 2 2 Faslodex oestrogen receptor antagonist first-line advanced breast cancer 2009 2009 Oncology Faslodex oestrogen receptor antagonist adjuvant 2009 2009 Symbicort Turbuhaler inhaled steroid fast onset, long-acting agonist Symbicort Maintenance and Reliever Approved 2 Therapy for asthma SMART Respiratory and Inflammation 4 5 Symbicort pMDI inhaled steroid fast onset, long-acting agonist asthma Filed Approved 2 4 Symbicort pMDI inhaled steroid fast onset, long-acting agonist COPD Filed 1H 2008 2 2 3 This compound is in Phase II III development.
Authorities stated these symptoms were already captured within the GERD label.
Text stating No clinical interaction with 4 5 naproxen or rofecoxib was approved.
To be supplemented in 2008 with data supporting two additional strengths.
US approval based on 12 years and above.
Therapy area Compound Areas under investigation Therapy area Compound Areas under investigation DISCONTINUED NCEs DISCONTINUED LINE EXTENSIONS Galida diabetes metabolic syndrome Cardiovascular Exanta prevention of stroke in AF AZD1092 diabetes Faslodex second-line after aromatase inhibitor failure Oncology Cardiovascular AZD8677 dyslipidaemia diabetes Iressa head and neck AZD7009 atrial fibrillation conversion Comments AZD8450 dyslipidaemia Exanta was withdrawn from the market in February 2006.
All other AZD9343 GERD project discontinuations were as a result of their failure to meet their AZD6538 GERD target product profiles.
Gastrointestinal AZD8081 functional GI disease AZD9272 GERD As disclosure of compound information is balanced by the business AZD9335 GERD need to maintain confidentiality, information in relation to some NXY-059 stroke compounds listed here has not been disclosed at this time.
AZD9272 anxiety Neuroscience AZD9335 neuropathic pain AZD7512 depression and anxiety AZD3778 indication rhinitis AZD2914 COPD AZD8955 OA Respiratory and AZD9056 COPD Inflammation AZD8309 RA AZD8309 COPD AZD3342 COPD
